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Abstract
 
The pattern recognition receptor, RAGE (receptor for advanced glycation endproducts), propagates
cellular dysfunction in several inflammatory disorders and diabetes. Here we show that RAGE
functions as an endothelial adhesion receptor promoting leukocyte recruitment. In an animal
model of thioglycollate-induced acute peritonitis, leukocyte recruitment was significantly impaired
in RAGE-deficient mice as opposed to wild-type mice. In diabetic wild-type mice we observed
enhanced leukocyte recruitment to the inflamed peritoneum as compared with nondiabetic
wild-type mice; this phenomenon was attributed to RAGE as it was abrogated in the presence
of soluble RAGE and was absent in diabetic RAGE-deficient mice. In vitro, RAGE-dependent
leukocyte adhesion to endothelial cells was mediated by a direct interaction of RAGE with the
 
 
 
2-integrin Mac-1 and, to a lower extent, with p150,95 but not with LFA-1 or with 
 
 
 
1-integrins.
The RAGE–Mac-1 interaction was augmented by the proinflammatory RAGE-ligand, S100-
protein. These results were corroborated by analysis of cells transfected with different heterodimeric
 
 
 
2-integrins, by using RAGE-transfected cells, and by using purified proteins. The RAGE–
Mac-1 interaction defines a novel pathway of leukocyte recruitment relevant in inflammatory
disorders associated with increased RAGE expression, such as in diabetes, and could provide the
basis for the development of novel therapeutic applications.
Key words: leukocyte • integrin • RAGE • diabetes • adhesion
 
Introduction
 
Leukocyte recruitment is an integral part of inflammatory
processes or vascular remodeling and requires multistep
adhesive and signaling events, including selectin-mediated
rolling, leukocyte activation, and integrin-mediated firm
adhesion and diapedesis (1). During firm adhesion of leu-
kocytes to the endothelium, members of the 
 
 
 
2-integrin
family, LFA-1 (
 
 
 
L
 
 
 
2, CD11a/CD18), Mac-1 (
 
 
 
M
 
 
 
2,
CD11b/CD18), and p150,95 (
 
 
 
X
 
 
 
2, CD11c/CD18), as
well as 
 
 
 
1-integrins on the leukocyte surface, interact
with endothelial counterligands such as ICAM-1, surface-
associated fibrinogen (FBG), or VCAM-1. However, addi-
tional, yet still undefined, counter-receptors might also be
engaged (2–4). In ICAM-1–deficient mice the defect in leu-
kocyte recruitment is not complete, therefore, the existence of
further 
 
 
 
2-integrin–dependent, ICAM-1–independent
mechanisms has been proposed (2). Furthermore, the impor-
tance of ICAM-1–dependent and ICAM-1–independent
mechanisms of leukocyte recruitment in different patho-
physiological situations, such as in diabetes, has not yet
been established.
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Abbreviations used in this paper:
 
 AGE, advanced glycation endproducts;
CML, (carboxymethyl)-lysine; FBG, fibrinogen; FN, fibronectin; HK,
high molecular weight kininogen; HUVEC, human umbilical vein endo-
thelial cells; RAGE, receptor for AGE.T
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The pattern recognition receptor RAGE, (receptor for
advanced glycation endproducts), has been implicated in
leukocyte migration (5, 6), however, the underlying mech-
anisms are not yet completely understood. RAGE is a mul-
tiligand receptor on vascular cells playing a key role in in-
flammatory processes. RAGE is expressed at low levels in
normal tissues and in the vasculature and becomes up-regu-
lated in the diabetic vasculature or at other sites where its
ligands accumulate (5, 7, 8). In particular, through recogni-
tion of 
 
 
 
-sheet fibrillar structures, RAGE binds amyloid
components, proinflammatory cytokine-like mediators of
the S100/calgranulin family, or amphoterin (9–11). In dia-
betic vessels, RAGE ligands also include AGEs (advanced
glycation endproducts) of at least two types, (carboxy-
methyl)-lysine (CML) adducts and hydroimidazolones (5,
12, 13). Binding of these ligands to RAGE initiates sus-
tained cellular activation mediated by receptor-dependent
signaling involving the transcription factor NF
 
 
 
B (14).
RAGE has been thought to promote the proinflammatory
phenotype of the diabetic vasculature (15–17), thereby par-
ticipating in diabetic vascular complications (18–20).
These diverse observations have prompted us to investi-
gate the role of RAGE in leukocyte recruitment. We dem-
onstrate here the existence of direct interactions between
RAGE and the 
 
 
 
2-integrin Mac-1 and p150,95 that define
RAGE as a new adhesion receptor and provide evidence
for a novel pathway of leukocyte recruitment that may be
relevant in pathophysiological situations including diabetes.
 
Materials and Methods
 
Materials.
 
The following reagents were provided from these
sources: Isolated Mac-1, LFA-1, and ICAM-1 (Dr. Sarah Bodary,
Genentech, CA); S100-B (Sigma-Aldrich); blocking mAb against
human CD18, 60.3 (IgG2a) (Dr. John Harlan, Seattle, WA); 
 
 
 
2-
integrin activating mAb, Kim185 (Dr. M. Robinson, Slough
Berkshire, UK); mAb L15 against LFA-1 (IgG2a) (Dr. C. Figdor,
Nijmegen, The Netherlands); mAb LPM19c against Mac-1
(IgG1) (Dr. A. May, Munich, Germany); mAb K20 against 
 
 
 
1-
chain (CD29) (IgG2a) and mAb HP2.1 against 
 
 
 
4-chain (IgG1),
(Immunotech); mAb against ICAM-1 (IgG1) (DakoCytomation);
respective isotype-matched control antibodies were from Dako-
Cytomation. The blocking mAb against mouse Mac-1 (M1/70)
(IgG2b) and mouse ICAM-1 (3E2) (IgG1), mAb against mouse
 
 
 
v
 
 
 
3 (RMV-7) (IgG1), as well as respective isotype-matched
control antibodies, which were used for in vivo inhibition studies,
were from BD Biosciences. MnCl
 
2
 
, FBG and fibronectin (FN)
(Sigma-Aldrich), vitamin D3 (BIOMOL Research Laboratories,
Inc.), transforming growth factor-
 
 
 
 (R&D Systems), high molec-
ular weight kininogen (HK) (Enzyme Research Laboratories).
Recombinant soluble mouse RAGE was expressed in Sf9 cells
and purified as described previously (21). In vitro synthesis of
CML-albumin was performed as described (14). Anti-RAGE
polyclonal antibody was raised in rabbit against KLH-conjugated
peptide, AQNITARIGEPLVLKC, that corresponds to the NH
 
2
 
terminus of mature human RAGE. Mouse RAGE has a highly
homologous sequence at the corresponding region, GQNITARI-
GEPLVLSC, thereby recombinant mouse RAGE is recognized
by this polyclonal antibody. Polyclonal anti-RAGE peptide anti-
body was purified by protein G chromatography.
 
Cell Culture and Adhesion Assay.
 
Myelo-monocytic U937
and THP-1 cells, K562 cells and K562 cells transfected with dif-
ferent 
 
 
 
2-integrin forms, as well as human umbilical vein endo-
thelial cells (HUVEC) were cultivated as previously described
(22–24). K562 cells (nontransfected, or stable LFA-1- or
p150,95-transfectants) were kindly provided by Dr. Y. van
Kooyk (University of Nijmegen, The Netherlands) and were cul-
tured in a mixture of 75% RPMI-1640 medium containing 10%
FCS and 25% ISCOVE’s medium supplemented with 5% FCS.
K562 cells transfected with Mac-1 were kindly provided by Dr.
M. Smith (Celltech, Slough, UK). Comparable expression of
LFA-1, p150,95, and Mac-1, respectively, of the transfected
K562 cells was confirmed by flow cytometry (22).
 
Generation of RAGE-transfected CHO Cells.
 
A full-length hu-
man RAGE cDNA was isolated from lung cDNA library by poly-
merase chain reaction with primers 5
 
 
 
-GATGGCAGCCGGAA-
CAGCAGTT-3
 
 
 
 and 5
 
 
 
-GAGGCCAGAACAGTTCAAGGG-3
 
 
 
.
Human RAGE cDNA was subcloned into an expression vector
under MPSV LTR promoter and used for transfection into CHO
cells as described previously (25). Surface expression of RAGE was
confirmed by flow cytometry analysis using mAb raised against
purified recombinant human soluble RAGE.
Human neutrophils were isolated from peripheral blood as
previously described (26).
Adhesion of U937 cells, THP-1 cells, K562 cells, or neutro-
phils to immobilized soluble RAGE (10 
 
 
 
g/ml) (and to BSA as
control) was performed as previously described (22–24). Briefly,
microtiter plates were coated with RAGE in bicarbonate buffer,
pH 9.6, and blocked with 3% BSA solution. Isolated human neu-
trophils, U937 cells, or THP-1 cells, which had been differenti-
ated for 24 h in the presence of vitamin D3 (100 nM) and trans-
forming growth factor-
 
 
 
 (2 ng/ml), or K562 cells were washed in
serum-free RPMI medium and plated onto the precoated wells
(10
 
5
 
/well) at 37
 
 
 
C for 60 min in the absence or presence of in-
hibitors. After the incubation period, the wells were washed and
adherent cells were fixed with methanol/acetone (1:1) at 4
 
 
 
C for
30 min. Adherent cells were then stained with crystal violet and
quantified by measuring absorbance at 590 nm.
Adhesion of U937 cells, THP-1 cells, or neutrophils to non-
transfected CHO cells, RAGE-transfected CHO cells, or cul-
tured HUVEC was tested as previously described (22, 26, 27).
Briefly, nontransfected CHO, RAGE-transfected CHO cells, or
HUVEC were grown to confluency onto 96-well plates. Fluores-
cence-labeled neutrophils (10
 
5
 
/well), differentiated U937 cells,
THP-1 cells, or K562 cells were washed twice, followed by no
pretreatment or stimulation with PMA (50 ng/ml) or the 
 
 
 
2-
integrin stimulating mAb Kim185 (10 
 
 
 
g/ml). Cells were washed
and added to CHO cells or HUVEC at 37
 
 
 
C for 60 min in the
absence or presence of inhibitors. After washing, adhesion of
neutrophils, U937 cells, THP-1 cells, or K562 cells was quanti-
fied as the percentage of total cells added using a fluorescence mi-
croplate reader (Bio-Tek) (22, 26, 27).
 
In Vitro Ligand-receptor Interactions.
 
Binding of biotinylated-
FBG or ICAM-1 to immobilized Mac-1 or LFA-1 was performed
as previously described (22, 26, 27). Alternatively, binding of solu-
ble RAGE (5 
 
 
 
g/ml) to immobilized Mac-1, LFA-1, or BSA
(each 5 
 
 
 
g/ml) was performed in TBS containing 0.3% BSA,
0.05% Tween-20. After incubation for 2 h at 22
 
 
 
C in each case, a
polyclonal antibody against RAGE was added, followed by addi-
tion of appropriate secondary peroxidase-conjugated antibody
(DakoCytomation) and the substrate ABTS, and binding was
quantitated at 405 nm. Nonspecific binding to BSA-coated wells
was used as blank and was subtracted to calculate specific binding.T
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Mice.
 
RAGE
 
 
 
/
 
 
 
 mice, tie2-RAGE mice, as well as tie2-
RAGE
 
 
 
RAGE
 
 
 
/
 
 
 
 mice (progeny of RAGE
 
 
 
/
 
 
 
 mice that were
crossed with tie2-RAGE transgenic mice, overexpressing RAGE
on the endothelium) were described previously (20, 28). Induc-
tion of diabetes with streptozotocin in wild-type and RAGE
 
 
 
/
 
 
 
mice was performed as previously described (29) and was ap-
proved by the Regional Commission in Giessen, Germany (File
No. Gi20/11–40/99).
 
In Vivo Peritonitis Model.
 
Thioglycollate-induced peritonitis
in diabetic or nondiabetic wild-type or RAGE
 
 
 
/
 
 
 
 mice was per-
formed as previously described (22, 27). For inhibition studies, 30
min before the injection of thioglycollate, the following com-
pounds were administered intraperitoneally: 100 
 
 
 
g mouse solu-
ble RAGE, or 100 
 
 
 
g mAb against mouse ICAM-1 in PBS.
Control mice were treated with the same volume of PBS, iso-
type-matched control antibodies (100 
 
 
 
g), or a mAb against
mouse 
 
 
 
v
 
 
 
3 (100 
 
 
 
g). To evaluate neutrophil recruitment, mice
were killed at 1 and 4 h after injection of thioglycollate, whereas
for monocyte/macrophage recruitment, mice were killed at 40
and 72 h after thioglycollate injection. Thereafter, the peritoneal
lavage was collected and the number of emigrated neutrophils or
macrophages was quantitated (22, 27, 30). There was no difference
in the circulating neutrophil count of the wild-type, RAGE
 
 
 
/
 
 
 
,
or tie2-RAGE
 
 
 
RAGE
 
 
 
/
 
 
 
 mice.
 
Statistical Analysis.
 
Data were analyzed by t test or analysis of
variance (ANOVA), as appropriate. P values of 
 
 
 
0.05 were re-
garded as significant. Statistical analysis of in vivo data: in Fig. 1,
A–D, data are presented as mean 
 
 
 
 SD. Fig. 1, A and B, were an-
alyzed by a two-way ANOVA with interaction term and appro-
priate contrasts to compare the groups. In case of interaction pair-
wise 
 
t
 
 tests were performed and the p-values are adjusted
according to the Holm procedure. Fig. 1 C was analyzed by a
one-way ANOVA and appropriate contrasts to compare the pairs
in case of a significant result for the global test. The closed test
procedure is used to guarantee the overall error rate of 0.05. Fig.
1 D was analyzed by a 
 
t
 
 test for unequal variances for 40 and 72 h,
respectively. Due to the fact that leukocyte count data are usually
not normally distributed, a nonparametric analysis was done for
sensitivity analysis.
 
Results
 
RAGE Mediates Leukocyte Recruitment In Vivo.
 
To test
whether RAGE is engaged in leukocyte recruitment in
vivo, we studied the role of RAGE in a mouse model of
acute inflammation. Peritonitis was induced by thioglycol-
late injection, and after four hours there was the expected
increase in the total leukocyte count in the peritoneum,
mostly attributable to emigrated neutrophils. The portion
of neutrophils among all leukocytes after four hours was
50–70% as compared with 3–5% at one hour after stimula-
tion (22, 27). This process is Mac-1 dependent, since treat-
ment with a blocking antibody against Mac-1 (administra-
tion 30 min before the induction of peritonitis) almost
completely abolished neutrophil extravasation into the in-
flamed peritoneum (27). Neutrophil recruitment to the
peritoneum was also significantly reduced in mice that
were pretreated with blocking mAb against ICAM-1
(
 
 
 
65–75% reduction), whereas an isotype-matched control
mAb or a mAb against an irrelevant endothelial antigen
Figure 1. The contribution of
RAGE to inflammatory reactions in
vivo. After thioglycollate injection
into the mouse peritoneum to induce
acute inflammation, the number of
neutrophils in the peritoneal lavage
was analyzed after 4 h. (A) Prior to
thioglycollate administration, nondia-
betic or diabetic mice were treated by
intraperitoneal injection with PBS
(black bars), with a blocking mAb
against ICAM-1 (gray bars), with solu-
ble RAGE (white bars), or a combina-
tion of the blocking mAb against
ICAM-1 and soluble RAGE (hatched
bars). *, P   0.0001 as compared with
control (nondiabetic mice treated with
PBS);   , P    0.0001 as compared
with control (diabetic mice treated
with PBS); #, P   0.001; ns, not sig-
nificant (P   0.1169). (B) The num-
ber of emigrated neutrophils into the
peritoneum of nondiabetic (black bars)
or diabetic (gray bars) wild-type or
RAGE /  mice was compared 4 h after
thioglycollate injection. *, P   0.0001;
#, P   0.0059; ns, not significant (P  
0.2656). (C) The number of neutro-
phils infiltrated into the peritoneum of
wild-type mice (black bars), RAGE / 
mice (white bars), or tie2-RAGE RAGE /  mice (gray bars) was compared 4 h after thioglycollate injection. *, P   0.0001; ns, not significant
(P   0.6976). (D) After thioglycollate injection into the mouse peritoneum the number of macrophages in the peritoneal lavage of wild-type (wt, black
bars) or RAGE  /  (white bars) mice was analyzed after 40 and 72 h. *, P   0.0001. Data are mean   SD (n   5 mice per treatment) of typical experiments;
similar results were obtained in three separate sets of experiments.T
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( v 3-integrin) did not inhibit (data not shown). Interest-
ingly, treatment with soluble RAGE also resulted in a par-
tial (25%) inhibition of neutrophil extravasation (Fig. 1 A).
Since RAGE is expressed at low levels in normal tissues
including the vasculature, and becomes up-regulated under
diabetic conditions, we performed the same model of acute
inflammation in diabetic mice. In diabetic mice, a twofold
increase in the recruited number of neutrophils to the in-
flamed peritoneum was observed when compared with
nondiabetic mice, whereas basal leukocyte counts (no
thioglycollate stimulation) in the peritoneum were similar
in both diabetic and nondiabetic mice (data not shown).
Again, neutrophil extravasation was almost completely
abolished by the use of blocking antibody against Mac-1
(data not shown). In diabetic mice, both soluble RAGE or
a blocking antibody against ICAM-1 reduced neutrophil
extravasation by  50%, and the combination of both in-
hibitors almost completely prevented neutrophil emigra-
tion (Fig. 1 A). These data indicate that in a setting where
RAGE is up-regulated, such as in diabetes, RAGE is di-
rectly involved in neutrophil recruitment.
To further test this hypothesis, we compared acute thio-
glycollate-induced peritonitis in wild-type and RAGE / 
mice. There was a significant reduction ( 30–40%) in
neutrophils that had migrated into the peritoneum of
RAGE /  mice as compared with wild-type mice (Fig. 1
B). Thioglycollate-elicited neutrophils isolated from the
peritoneum of wild-type or RAGE /  mice, respectively,
showed no significant difference in the expression of adhe-
sion receptors, in particular  1- and  2-integrins (data not
shown). Moreover, neutrophils isolated from wild-type
and RAGE /  mice showed comparable adhesion to FBG
and FN in vitro (data not shown). The increased neutro-
phil extravasation into the peritoneum that was observed in
diabetic wild-type mice was not found in diabetic RAGE / 
mice (Fig. 1 B). There was no difference in the basal (no
thioglycollate stimulation) counts of peritoneal leukocytes
between wild-type and RAGE /  mice irrespective of
whether the mice were diabetic (data not shown).
The decrease in neutrophil extravasation observed in
RAGE /  mice as compared with wild-type mice could be
reversed by restoring the expression of RAGE on endothe-
lial cells. Progeny of RAGE /  mice that were crossed
with tie2-RAGE transgenic mice, which overexpress
RAGE on the endothelium, showed comparable neutro-
phil extravasation as wild-type mice (Fig. 1 C). Therefore,
the described difference in neutrophil emigration between
wild-type and RAGE /  mice was indeed due to the ab-
sence of RAGE on the endothelium.
Finally, the same peritonitis model was extended for 40
and 72 h following thioglycollate administration, to evalu-
ate the recruitment of monocytes/macrophages into the
peritoneum in wild-type and RAGE /  mice. There was a
significant reduction ( 50%) in the number of macro-
phages that had migrated into the peritoneum of RAGE / 
mice as compared with wild-type mice (Fig. 1 D).
Together, these data demonstrate that RAGE mediates
leukocyte recruitment in vivo.
Integrin-mediated Leukocyte Adhesion to RAGE. Since
these observations suggested a direct participation of
RAGE in leukocyte extravasation, we studied whether leu-
kocytes can directly adhere to immobilized RAGE. Hu-
man peripheral blood neutrophils adhered strongly to
RAGE-coated plates dependent on the presence of diva-
lent cations (Fig. 2 A). Soluble RAGE and a blocking mAb
against   2-integrin abolished this adhesion, whereas a
blocking mAb against  1-integrin or a mAb against  4-
integrin had no effect. Moreover, neutrophil and my-
elomonocytic cell adhesion to immobilized RAGE was
inhibited by a blocking mAb against Mac-1, whereas a
blocking mAb against LFA-1, or isotype-matched control
mAbs (unpublished data) did not affect cell adhesion (Fig. 2
A). The Mac-1 ligand FBG, but not the  1-integrin ligand
FN, interfered with the adhesion of neutrophils to immo-
bilized RAGE (unpublished data). The same interaction
pattern between RAGE and Mac-1 was seen when the ad-
hesion of neutrophils to CHO cells transfected with RAGE
was tested (Fig. 2 B), whereas no appreciable adhesion to
nontransfected CHO cells was observed. Similar results
were obtained when the adhesion of THP-1 cells or U937
cells to immobilized RAGE or RAGE-transfected CHO
cells (and nontransfected CHO cells as control) was investi-
gated (unpublished data).
Figure 2. The adhesive properties of RAGE. (A) Adhesion of PMA-
stimulated human neutrophils to immobilized RAGE is shown in the
absence (-) or presence of EDTA (5 mM), soluble RAGE (10  g/ml),
mAb to  1-integrin, mAb to  2-integrin, mAb to Mac-1, mAb to LFA-1,
or mAb to  4-integrin (each antibody at 20  g/ml). (B) Adhesion of
PMA-stimulated human neutrophils to CHO cells (gray bars) or RAGE-
transfected CHO cells (black bars) is shown in the absence (-) or presence
of mAb to  1-integrin, mAb to  2-integrin, mAb to Mac-1, or mAb to
LFA-1 (each antibody at 20  g/ml), or soluble RAGE (10  g/ml). Cell
adhesion is represented either as absorbance of labeled cells at 590 nm or
as percentage of total added cells. All data are mean   SD (n   3) of a
typical experiment, similar results were obtained in at least three separate
experiments.T
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To further characterize the binding between RAGE and
 2-integrins, the adhesion of K562 erythroleukemic cells
transfected with either LFA-1, Mac-1, or another  2-inte-
grin, p150,95, to immobilized RAGE was studied (Fig. 3
A). Whereas nontransfected K562 cells or LFA-1 transfec-
tants did not show any appreciable adhesion to RAGE,
both under unstimulated or stimulated conditions (using
the stimulating  2-integrin antibody Kim185), K562 cells
expressing Mac-1 as well as p150,95 adhered to immobi-
lized RAGE in the presence of the  2-integrin stimulating
antibody Kim185. Similarly, only Mac-1- or p150,95-
transfected K562 cells adhered to RAGE-transfected CHO
cells, whereas LFA-1 transfectants or nontransfected cells
did not adhere (Fig. 3 B). None of the K562 cells inter-
acted with nontransfected parental CHO cells, indicating
that the observed interaction was dependent on the expres-
sion of RAGE. Adhesion of Mac-1–transfected cells to im-
mobilized RAGE or RAGE-transfected CHO cells was in-
hibited by blocking mAb against Mac-1, as well as by
soluble RAGE (Fig. 3 C). These data demonstrate for the
first time that RAGE acts as a counter-receptor for the  2-
integrin Mac-1 as well as p150,95 and is capable of mediat-
ing heterophilic cell–cell interactions.
We then tested, whether endothelial RAGE could also
mediate leukocyte–endothelial interactions. Both mAb
against ICAM-1 and soluble RAGE could partially block
Mac-1–dependent adhesion of human neutrophils to endo-
thelial cell monolayer. The combination of ICAM-1 and
RAGE blockade almost completely abolished neutrophil
Figure 3. RAGE is a counter-receptor for  2-integrins. (A) Adhesion
of nontransfected K562 cells, LFA-1-transfected K562 cells, Mac-1-
transfected K562 cells, or p150,95-transfected K562 to immobilized
RAGE is shown in the absence (gray bars) or presence (black bars) of  2-
integrin–stimulating antibody Kim185 (10  g/ml). (B) Adhesion of non-
transfected K562 cells, LFA-1–transfected K562 cells, Mac-1–transfected
K562 cells, or p150,95-transfected K562 cells, which were preincubated
with Kim185 (10  g/ml), to nontransfected CHO cells (gray bars) or
RAGE-transfected CHO cells (black bars) is shown. (C) Adhesion of
Mac-1–transfected K562 cells, which were preincubated with Kim185
(10  g/ml), to RAGE-transfected CHO cells is shown in the absence (-)
or presence of mAb to Mac-1 (20  g/ml) or soluble RAGE (10  g/ml).
Cell adhesion is represented either as absorbance at 590 nm or as percentage
of total added cells. All data are mean   SD (n   3) of a typical experiment,
similar results were observed in at least three separate experiments.
Figure 4. Contribution of RAGE to neutrophil adhesion to cultured
endothelial cells. PMA-stimulated adhesion of human neutrophils to
endothelial cells is shown in the absence (-) or presence of mAb to  2-
integrin, mAb to Mac-1, mAb to ICAM-1 (each antibody at 20  g/ml),
soluble RAGE (10  g/ml), or a combination of soluble RAGE and mAb
to ICAM-1. Cell adhesion is represented as percentage of total added
cells. All data are mean   SD (n   3) of a typical experiment, similar results
were observed in at least three separate experiments.
Figure 5. The interaction between RAGE and Mac-1. (A) The binding
of ICAM-1 or soluble RAGE (each 5  g/ml) to immobilized LFA-1
(gray bars) or Mac-1 (black bars) is shown. (B) Dose-dependent specific
binding of soluble RAGE to immobilized Mac-1 is shown. Specific binding
is expressed as absorbance at 405 nm. Data are mean   SD (n   3) of a
typical experiment; similar results were observed in at least three separate
experiments.T
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adhesion to endothelial cells (Fig. 4). Isotype-matched con-
trol mAbs had no inhibitory effect (data not shown). Taken
together, these results clearly demonstrate that RAGE can
act as a novel adhesive counter-receptor for  2-integrin–
dependent leukocyte–endothelial interactions.
Binding Interactions Between Mac-1 and RAGE. Since
the previous observations implicated that there might be a
direct binding of RAGE to the  2-integrin Mac-1, the in-
teraction of soluble RAGE with immobilized purified
Mac-1 or LFA-1 was analyzed. Soluble RAGE bound di-
rectly to Mac-1, and this binding was equivalent in its ex-
tent to the binding of ICAM-1 to this integrin (Fig. 5 A).
Moreover, binding of soluble RAGE to Mac-1 was dose-
dependent and saturable (Fig. 5 B). In contrast, no specific
binding of soluble RAGE to immobilized LFA-1 was ob-
served, while the expected binding of ICAM-1 to LFA-1
was apparent.
To further characterize the interaction between RAGE
and Mac-1, we tested whether the major ligand-binding
I-domain of Mac-1, as well as other Mac-1 ligands, can com-
pete for the binding of soluble RAGE to Mac-1. Here, the
isolated I-domain of Mac-1 completely abolished binding
of RAGE to Mac-1 (Fig. 6 A), and binding of soluble
RAGE to Mac-1 was blocked by both FBG and HK
(IC50: 150 nM or 200 nM, respectively; Fig. 6 B). In con-
trast, the endothelial Mac-1 ligand, ICAM-1, had no in-
hibitory effect on binding of soluble RAGE at all (Fig. 6
A). Moreover, RAGE could also block the binding of FBG
to Mac-1 (IC50:  175 nM; Fig. 6 C). These data indicate
that the major ligand-binding I-domain of Mac-1 is in-
volved in RAGE binding and that the binding site for
RAGE on Mac-1 overlaps with the binding sites of other
ligands, such as FBG and HK (22).
For further characterization of the RAGE–Mac-1 inter-
action we examined whether two RAGE ligands, CML-
modified albumin and S100-B protein, could interfere with
the interaction between RAGE and Mac-1. While CML
did not affect the binding of RAGE to immobilized Mac-1
at all, S100-B protein augmented this interaction more
than twofold in a dose-dependent, saturable manner (Fig. 7
A). A similar approximate twofold increase of Mac-1–depen-
dent adhesion of myelomonocytic U937 cells to RAGE
was observed in the presence of S100-B protein (Fig. 7 B).
No direct interaction between Mac-1 and S100 was ob-
served (unpublished data). Taken together, these data dem-
onstrate that RAGE directly interacts with Mac-1 and that
Figure 6. Influence of Mac-1 ligands on the interaction between
RAGE and Mac-1. (A) The specific binding of soluble RAGE (100 nM)
to immobilized Mac-1 is shown in the absence (-) or presence of FBG,
HK, ICAM-1, or the isolated I-domain of Mac-1 (each 500 nM). (B) The
specific binding of soluble RAGE (100 nM) to immobilized Mac-1 is
shown in the absence or presence of increasing concentrations of FBG
(black circles) or HK (white squares). (C) The specific binding of FBG
(100 nM) to immobilized Mac-1 is shown in the absence or presence of
increasing concentrations of soluble RAGE. Specific binding is expressed
as absorbance at 405 nm. Data are mean   SD (n   3) of a typical experi-
ment; similar results were observed in at least three separate experiments.
Figure 7. Influence of RAGE ligands on the interaction between
RAGE and Mac-1. (A) The specific binding of soluble RAGE (5  g/ml)
to immobilized Mac-1 is shown in the absence or presence of increasing
concentrations of S100-B (black circles) or CML (white squares). Specific
binding is expressed as absorbance at 405 nm. Data are mean   SD (n   3)
of a typical experiment; similar results were observed in at least three separate
experiments. (B) PMA-stimulated adhesion of U937 cells to immobilized
RAGE is presented in the absence (-) or presence of mAb to Mac-1
(20  g/ml), CML (800 nM), S100-B (800 nM), or the combination of
S100-B and mAb to Mac-1. Cell adhesion is represented as percent of
control. Data are mean   SD (n   3) of a typical experiment; similar results
were observed in at least three separate experiments.T
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this interaction is enhanced by another RAGE ligand,
S100-B protein, but not by CML-adducts.
Discussion
The present report demonstrates that RAGE serves as a
novel counter-receptor for the leukocyte integrin Mac-1,
being directly involved in leukocyte recruitment in vitro
and in vivo. RAGE is a central player in inflammation (5)
and in diabetic complications (5, 20) and our findings help
to clarify its functional role. Our data show that RAGE
serves as a binding partner for the  2-integrins Mac-1 and
p150,95, in addition to the classical counter-receptor
ICAM-1. Although ICAM-1 is the major endothelial cell
ligand of both Mac-1 and LFA-1, its exclusive expression
on the inflammatory endothelium could not account for
the entire phenomenon of leukocyte adhesion and extrava-
sation (2, 31). Thus, RAGE is a counter-receptor for leu-
kocyte integrins that contributes to the recruitment of in-
flammatory cells, particularly under stress or pathological
conditions such as in diabetes.
The following features are consistent with a specific in-
teraction of RAGE, particularly with the leukocyte  2-
integrin Mac-1. i, Neutrophils and myelomonocytic cells
adhered to immobilized RAGE or RAGE-transfected cells,
and this interaction was attributable to Mac-1. ii, Adhesion
of K562 cells transfected with different  2-integrins to ei-
ther immobilized RAGE or RAGE-transfected cells fur-
ther established that RAGE interacts with Mac-1, but not
with LFA-1. Interestingly, K562 cells bearing a third  2-
integrin, p150,95, also interacted with RAGE, which is not
surprising, as p150,95 and Mac-1 share many structural fea-
tures in ligand binding (26). iii, In a purified system, a di-
rect binding between RAGE and Mac-1 was observed.
RAGE interacts with the ligand-binding I-domain of Mac-1.
Competition studies indicated that the binding site of
RAGE overlaps with those of established Mac-1 ligands,
such as FBG and HK, and that the affinity of the RAGE–
Mac-1 interaction falls into a similar range as compared
with these Mac-1 ligands. Binding of RAGE to Mac-1 was
augmented by a RAGE-ligand, S100-B protein, whereas
another RAGE ligand, CML, had no influence, suggesting
that the formation of a ternary complex between Mac-1,
RAGE, and S100 is likely and needs further experimental
proof. Moreover, our observations are in agreement with a
previous report demonstrating Mac-1 activation by another
S100 family member, S100-A9 (32). Based on these data
we postulate that RAGE constitutes an adhesive receptor
mediating intercellular contacts. The possibility that RAGE
also interacts with Mac-1 in a cis fashion on leukocytes and
that this interaction is enhanced in the presence of S100
proteins needs to be addressed in future studies.
RAGE mediates leukocyte recruitment in vivo, as we
observed in the model of thioglycollate-induced acute
peritonitis, and in vitro studies indicate that it likely does so
by interacting with Mac-1. RAGE-mediated leukocyte re-
cruitment was more prominent in diabetic mice in which
RAGE was up-regulated. While RAGE only partially con-
tributed to leukocyte recruitment in vivo in control mice,
in diabetic mice a higher percentage of leukocyte recruit-
ment was inhibited by soluble RAGE. Moreover, the in-
crease in neutrophil extravasation due to the diabetes ob-
served in wild-type mice was not present in RAGE / 
mice. These results support the conclusion that RAGE-
mediated leukocyte recruitment becomes more important
as RAGE expression increases at the site of inflammation.
Finally, in RAGE /  mice, a significant reduction ( 50%)
of macrophages migrating into the peritoneum was ob-
served as compared with wild-type mice, indicative for the
importance of RAGE in the progression of chronic inflam-
matory processes related to macroangioapathies.
While RAGE is expressed at low levels in normal tissues
and the vasculature, the receptor becomes up-regulated
wherever its ligands may accumulate (5). Thus, the mecha-
nism for leukocyte recruitment presented here may be par-
ticularly applicable in pathophysiological conditions associ-
ated with high RAGE expression, such as in diabetes,
chronic immune responses, atherosclerosis, or cancer (5,
10, 11). Simultaneously, an increased RAGE expression
will lead to further RAGE-dependent cellular activation
and dysfunction (5, 8). Engagement of RAGE by its ligands,
such as AGE, thereby increases the permeability of the vas-
cular endothelium and may elevate the expression of adhe-
sion molecules, such as VCAM-1, procoagulant tissue fac-
tor, or proinflammatory interleukin-6 (15–17, 33), probably
through RAGE–mediated activation of NF B pathways.
Thus, RAGE-mediated cellular activation may explain the
increased recruitment of inflammatory cells. However, the
data presented here demonstrate that in addition to
RAGE-mediated cellular activation, RAGE can directly
modulate leukocyte recruitment as it acts as an endothelial
cell adhesive receptor attracting leukocytes.
RAGE is implicated in diabetic complications, particu-
larly in accelerated atherosclerosis of the diabetic vessel wall
(18–20, 29, 34, 35). Since increased leukocyte recruitment
is a prominent feature of the atherosclerotic vasculature, it
is possible that the RAGE-dependent leukocyte adhesion
defined here could contribute to the proatherogenic phe-
notype of the diabetic vessel. This is supported by previous
observations in which soluble RAGE was shown to sup-
press the diabetes-associated accelerated atherosclerosis of
animals deficient in apoE (18, 29, 35).
Although in previous studies amelioration of the inflam-
matory response in several pathophysiologies with soluble
RAGE was demonstrated and attributed to its propensity to
interfere with RAGE-mediated cellular activation, the
present findings define soluble RAGE as a potential inhibi-
tor of leukocyte recruitment. The interference of soluble
RAGE with such a central interaction in the immune re-
sponse also provides a further explanation for its broad
spectrum of functions. Finally, antagonizing the interaction
between RAGE and  2-integrins might provide a novel
therapeutic antiinflammatory strategy in diabetes or chronic
immune responses associated with high RAGE expression.T
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